Heterogeneity in Liver Cancer Immune Microenvironment: Emerging Single-Cell and Spatial Perspectives

Abstract

Primary liver cancer is a solid malignancy with a high mortality rate. The success of immunotherapy has shown great promise in improving patient care and highlights a crucial need to understand the complexity of the liver tumor immune microenvironment (TIME). Recent advances in single-cell and spatial omics technologies, coupled with the development of systems biology approaches, are rapidly transforming the landscape of tumor immunology. Here we review the cellular landscape of liver TIME from single-cell and spatial perspectives. We also discuss the cellular interaction networks within the tumor cell community in regulating immune responses. We further highlight the challenges and opportunities with implications for biomarker discovery, patient stratification, and combination immunotherapies.

Keywords

liver cancer - tumor immune microenvironment - immunotherapy - single cell and spatial omics - tumor heterogeneity

Authors' Contributions

L.M. developed study concept; C.C.L., M.L., H-P.L., W.W., and L.M. wrote the manuscript. All authors read, edited, and approved the manuscript.

^* Contributed equally to this manuscript.

Publikationsverlauf

Artikel online veröffentlicht:
24. Mai 2024

• References

• 1 Llovet JM, Kelley RK, Villanueva A. et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021; 7 (01) 6
• 2 Loeuillard E, Conboy CB, Gores GJ, Rizvi S. Immunobiology of cholangiocarcinoma. JHEP Rep Innov Hepatol 2019; 1 (04) 297-311
• 3 Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 2015; 261 (05) 947-955
• 4 Greten TF, Sangro B. Targets for immunotherapy of liver cancer. J Hepatol 2017
• 5 Martin SP, Wang XW. The evolving landscape of precision medicine in primary liver cancer. Hepat Oncol 2019; 6 (02) HEP12
• 6 Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021; 18 (08) 525-543
• 7 Cheng AL, Qin S, Ikeda M. et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022; 76 (04) 862-873
• 8 Greten TF, Villanueva A, Korangy F. et al. Biomarkers for immunotherapy of hepatocellular carcinoma. Nat Rev Clin Oncol 2023; 20 (11) 780-798
• 9 Binnewies M, Roberts EW, Kersten K. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018; 24 (05) 541-550
• 10 Budhu A, Pehrsson EC, He A. et al. Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy. Cell Rep Med 2023; 4 (06) 101052
• 11 Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology 2006; 43 (2, Suppl 1): S54-S62
• 12 MacParland SA, Liu JC, Ma XZ. et al. Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. Nat Commun 2018; 9 (01) 4383
• 13 Kurioka A, Walker LJ, Klenerman P, Willberg CB. MAIT cells: new guardians of the liver. Clin Transl Immunology 2016; 5 (08) e98
• 14 Giraud J, Chalopin D, Blanc JF, Saleh M. Hepatocellular carcinoma immune landscape and the potential of immunotherapies. Front Immunol 2021; 12: 655697
• 15 Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer 2021; 21 (09) 541-557
• 16 Thorsson V, Gibbs DL, Brown SD. et al; Cancer Genome Atlas Research Network. The immune landscape of cancer. Immunity 2018; 48 (04) 812-830.e14
• 17 Barkley D, Moncada R, Pour M. et al. Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment. Nat Genet 2022; 54 (08) 1192-1201
• 18 Christo SN, Evrard M, Park SL. et al. Discrete tissue microenvironments instruct diversity in resident memory T cell function and plasticity. Nat Immunol 2021; 22 (09) 1140-1151
• 19 Ma L, Hernandez MO, Zhao Y. et al. Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer. Cancer Cell 2019; 36 (04) 418-430.e6
• 20 Mempel TR, Lill JK, Altenburger LM. How chemokines organize the tumour microenvironment. Nat Rev Cancer 2024; 24 (01) 28-50
• 21 Yang F, Hilakivi-Clarke L, Shaha A. et al. Metabolic reprogramming and its clinical implication for liver cancer. Hepatology 2023; 78 (05) 1602-1624
• 22 Liu J, Dang H, Wang XW. The significance of intertumor and intratumor heterogeneity in liver cancer. Exp Mol Med 2018; 50 (01) e416
• 23 Pfister D, Núñez NG, Pinyol R. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021; 592 (7854) 450-456
• 24 de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 2023; 41 (03) 374-403
• 25 van Vlerken-Ysla L, Tyurina YY, Kagan VE, Gabrilovich DI. Functional states of myeloid cells in cancer. Cancer Cell 2023; 41 (03) 490-504
• 26 Dolina JS, Van Braeckel-Budimir N, Thomas GD, Salek-Ardakani S. CD8⁺ T cell exhaustion in cancer. Front Immunol 2021; 12: 715234
• 27 Sharma P, Siddiqui BA, Anandhan S. et al. The next decade of immune checkpoint therapy. Cancer Discov 2021; 11 (04) 838-857
• 28 Zhang N, Bevan MJ. CD8(+) T cells: foot soldiers of the immune system. Immunity 2011; 35 (02) 161-168
• 29 Speiser DE, Chijioke O, Schaeuble K, Münz C. CD4⁺ T cells in cancer. Nat Cancer 2023; 4 (03) 317-329
• 30 St Paul M, Ohashi PS. The roles of CD8⁺ T cell subsets in antitumor immunity. Trends Cell Biol 2020; 30 (09) 695-704
• 31 Duan M, Goswami S, Shi JY. et al. Activated and exhausted MAIT cells foster disease progression and indicate poor outcome in hepatocellular carcinoma. Clin Cancer Res 2019; 25 (11) 3304-3316
• 32 Kotsari M, Dimopoulou V, Koskinas J, Armakolas A. Immune system and hepatocellular carcinoma (HCC): new insights into HCC progression. Int J Mol Sci 2023; 24 (14) 24
• 33 Doherty DG, O'Farrelly C. Innate and adaptive lymphoid cells in the human liver. Immunol Rev 2000; 174: 5-20
• 34 Ruf B, Bruhns M, Babaei S. et al. Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin. Cell 2023; 186 (17) 3686-3705.e32
• 35 Zhao N, Dang H, Ma L. et al. Intratumoral γδ T-cell infiltrates, chemokine (C-C motif) ligand 4/chemokine (C-C motif) ligand 5 protein expression and survival in patients with hepatocellular carcinoma. Hepatology 2021; 73 (03) 1045-1060
• 36 He W, Hu Y, Chen D. et al. Hepatocellular carcinoma-infiltrating γδ T cells are functionally defected and allogenic Vδ2⁺ γδ T cell can be a promising complement. Clin Transl Med 2022; 12 (04) e800
• 37 Chandwaskar R, Awasthi A. Emerging roles of Th9 cells as an anti-tumor helper T cells. Int Rev Immunol 2019; 38 (05) 204-211
• 38 Bian J, Lin J, Long J. et al. T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy. Am J Cancer Res 2020; 10 (12) 4585-4606
• 39 Chen X, Du Y, Hu Q, Huang Z. Tumor-derived CD4+CD25+regulatory T cells inhibit dendritic cells function by CTLA-4. Pathol Res Pract 2017; 213 (03) 245-249
• 40 Ono M. Control of regulatory T-cell differentiation and function by T-cell receptor signalling and Foxp3 transcription factor complexes. Immunology 2020; 160 (01) 24-37
• 41 Tan H, Wang S, Zhao L. A tumour-promoting role of Th9 cells in hepatocellular carcinoma through CCL20 and STAT3 pathways. Clin Exp Pharmacol Physiol 2017; 44 (02) 213-221
• 42 Lee HL, Jang JW, Lee SW. et al. Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization. Sci Rep 2019; 9 (01) 3260
• 43 Budhu A, Forgues M, Ye QH. et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006; 10 (02) 99-111
• 44 Zhang JP, Yan J, Xu J. et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009; 50 (05) 980-989
• 45 Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol 2009; 183 (07) 4169-4175
• 46 Qin S, Ma S, Huang X, Lu D, Zhou Y, Jiang H. Th22 cells are associated with hepatocellular carcinoma development and progression. Chin J Cancer Res 2014; 26 (02) 135-141
• 47 Zhang J, Liu Z, Liu L, Huang M, Huang Y. Th22/IL-22 mediates the progression of HBV-related hepatocellular carcinoma via STAT3. Cytotechnology 2022; 74 (02) 203-216
• 48 Duhen T, Duhen R, Lanzavecchia A, Sallusto F, Campbell DJ. Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood 2012; 119 (19) 4430-4440
• 49 Bhairavabhotla R, Kim YC, Glass DD. et al. Transcriptome profiling of human FoxP3+ regulatory T cells. Hum Immunol 2016; 77 (02) 201-213
• 50 Zheng C, Zheng L, Yoo JK. et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 2017; 169 (07) 1342-1356.e16
• 51 Mittermüller D, Otto L, Long Z. et al. Regulatory T cells suppress the motility of cytotoxic T cells in friend retrovirus-infected mice. JCI Insight 2023; 8 (13) 8
• 52 Chauhan P, Hu S, Sheng WS, Lokensgard JR. Regulatory T-cells suppress cytotoxic T lymphocyte responses against microglia. Cells 2022; 11 (18) 11
• 53 Fu J, Xu D, Liu Z. et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132 (07) 2328-2339
• 54 Yang Y, Liu F, Liu W. et al. Analysis of single-cell RNAseq identifies transitional states of T cells associated with hepatocellular carcinoma. Clin Transl Med 2020; 10 (03) e133
• 55 Chaoul N, Mancarella S, Lupo L, Giannelli G, Dituri F. Impaired anti-tumor T cell response in hepatocellular carcinoma. Cancers (Basel) 2020; 12 (03) 12
• 56 Böttcher JP, Beyer M, Meissner F. et al. Functional classification of memory CD8(+) T cells by CX3CR1 expression. Nat Commun 2015; 6: 8306
• 57 Xue R, Zhang Q, Cao Q. et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature 2022; 612 (7938) 141-147
• 58 Schietinger A, Philip M, Krisnawan VE. et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity 2016; 45 (02) 389-401
• 59 Khan O, Giles JR, McDonald S. et al. TOX transcriptionally and epigenetically programs CD8⁺ T cell exhaustion. Nature 2019; 571 (7764) 211-218
• 60 Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 2015; 125 (09) 3384-3391
• 61 Budimir N, Thomas GD, Dolina JS, Salek-Ardakani S. Reversing T-cell exhaustion in cancer: lessons learned from PD-1/PD-L1 immune checkpoint blockade. Cancer Immunol Res 2022; 10 (02) 146-153
• 62 Zheng L, Qin S, Si W. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 2021; 374 (6574) abe6474
• 63 Barsch M, Salié H, Schlaak AE. et al. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. J Hepatol 2022; 77 (02) 397-409
• 64 Ma L, Wang L, Khatib SA. et al. Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Hepatol 2021; 75 (06) 1397-1408
• 65 Cappuyns S, Philips G, Vandecaveye V. et al. PD-1^- CD45RA⁺ effector-memory CD8 T cells and CXCL10⁺ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma. Nat Commun 2023; 14 (01) 7825
• 66 Magen A, Hamon P, Fiaschi N. et al. Intratumoral dendritic cell-CD4⁺ T helper cell niches enable CD8⁺ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat Med 2023; 29 (06) 1389-1399
• 67 Laumont CM, Nelson BH. B cells in the tumor microenvironment: multi-faceted organizers, regulators, and effectors of anti-tumor immunity. Cancer Cell 2023; 41 (03) 466-489
• 68 Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol 2015; 15 (03) 149-159
• 69 Kinker GS, Vitiello GAF, Ferreira WAS, Chaves AS, Cordeiro de Lima VC, Medina TDS. B cell orchestration of anti-tumor immune responses: a matter of cell localization and communication. Front Cell Dev Biol 2021; 9: 678127
• 70 Morgan D, Tergaonkar V. Unraveling B cell trajectories at single cell resolution. Trends Immunol 2022; 43 (03) 210-229
• 71 Zhang Z, Ma L, Goswami S. et al. Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma. OncoImmunology 2019; 8 (04) e1571388
• 72 Garnelo M, Tan A, Her Z. et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut 2017; 66 (02) 342-351
• 73 Zhang S, Liu Z, Wu D, Chen L, Xie L. Single-cell RNA-Seq analysis reveals microenvironmental infiltration of plasma cells and hepatocytic prognostic markers in HCC with cirrhosis. Front Oncol 2020; 10: 596318
• 74 Xu Y, Wei Z, Feng M. et al. Tumor-infiltrated activated B cells suppress liver metastasis of colorectal cancers. Cell Rep 2022; 40 (09) 111295
• 75 Zhang S, Yuan L, Danilova L. et al. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence. Genome Med 2023; 15 (01) 72
• 76 Helmink BA, Reddy SM, Gao J. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 2020; 577 (7791) 549-555
• 77 Ma L, Heinrich S, Wang L. et al. Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer. Nat Commun 2022; 13 (01) 7533
• 78 Mi H, Ho WJ, Yarchoan M, Popel AS. Multi-scale spatial analysis of the tumor microenvironment reveals features of cabozantinib and nivolumab efficacy in hepatocellular carcinoma. Front Immunol 2022; 13: 892250
• 79 Sharma A, Seow JJW, Dutertre CA. et al. Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma. Cell 2020; 183 (02) 377-394.e21
• 80 Zhang M, Yang H, Wan L. et al. Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. J Hepatol 2020; 73 (05) 1118-1130
• 81 Zheng H, Peng X, Yang S. et al. Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy. Cell Death Discov 2023; 9 (01) 65
• 82 Arvanitakis K, Koletsa T, Mitroulis I, Germanidis G. Tumor-associated macrophages in hepatocellular carcinoma pathogenesis, prognosis and therapy. Cancers (Basel) 2022; 14 (01) 14
• 83 Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol 2017; 10 (01) 58
• 84 Zhang YL, Li Q, Yang XM. et al. SPON2 promotes M1-like macrophage recruitment and inhibits hepatocellular carcinoma metastasis by distinct integrin-rho GTPase-Hippo pathways. Cancer Res 2018; 78 (09) 2305-2317
• 85 Wang YF, Yuan SX, Jiang H. et al. Spatial maps of hepatocellular carcinoma transcriptomes reveal spatial expression patterns in tumor immune microenvironment. Theranostics 2022; 12 (09) 4163-4180
• 86 Song G, Shi Y, Zhang M. et al. Global immune characterization of HBV/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression. Cell Discov 2020; 6 (01) 90
• 87 Ma RY, Black A, Qian BZ. Macrophage diversity in cancer revisited in the era of single-cell omics. Trends Immunol 2022; 43 (07) 546-563
• 88 Liu Y, Xun Z, Ma K. et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol 2023; 78 (04) 770-782
• 89 Xun Z, Ding X, Zhang Y. et al. Reconstruction of the tumor spatial microenvironment along the malignant-boundary-nonmalignant axis. Nat Commun 2023; 14 (01) 933
• 90 Zhang Q, He Y, Luo N. et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell 2019; 179 (04) 829-845.e20
• 91 Li Z, Pai R, Gupta S. et al. Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy. Nat Cancer 2024; 5 (01) 167-186
• 92 Duan Z, Luo Y. Targeting macrophages in cancer immunotherapy. Signal Transduct Target Ther 2021; 6 (01) 127
• 93 Wang Q, Lin Y, Yu W, Chen X, He Q, Ye Z. The core role of macrophages in hepatocellular carcinoma: the definition of molecular subtypes and the prognostic risk system. Front Pharmacol 2023; 14: 1228052
• 94 Geh D, Leslie J, Rumney R, Reeves HL, Bird TG, Mann DA. Neutrophils as potential therapeutic targets in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2022; 19 (04) 257-273
• 95 Fridlender ZG, Sun J, Kim S. et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 2009; 16 (03) 183-194
• 96 Grieshaber-Bouyer R, Radtke FA, Cunin P. et al; ImmGen Consortium. The neutrotime transcriptional signature defines a single continuum of neutrophils across biological compartments. Nat Commun 2021; 12 (01) 2856
• 97 Meng Y, Ye F, Nie P. et al. Immunosuppressive CD10⁺ALPL⁺ neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells. J Hepatol 2023; 79 (06) 1435-1449
• 98 Bald T, Krummel MF, Smyth MJ, Barry KC. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat Immunol 2020; 21 (08) 835-847
• 99 Mikulak J, Bruni E, Oriolo F, Di Vito C, Mavilio D. Hepatic natural killer cells: organ-specific sentinels of liver immune homeostasis and physiopathology. Front Immunol 2019; 10: 946
• 100 Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The broad spectrum of human natural killer cell diversity. Immunity 2017; 47 (05) 820-833
• 101 Stegmann KA, Robertson F, Hansi N. et al. CXCR6 marks a novel subset of T-bet(lo)Eomes(hi) natural killer cells residing in human liver. Sci Rep 2016; 6: 26157
• 102 Hudspeth K, Donadon M, Cimino M. et al. Human liver-resident CD56(bright)/CD16(neg) NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. J Autoimmun 2016; 66: 40-50
• 103 Zhao J, Zhang S, Liu Y. et al. Single-cell RNA sequencing reveals the heterogeneity of liver-resident immune cells in human. Cell Discov 2020; 6: 22
• 104 Wu M, Mei F, Liu W, Jiang J. Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles. Biomed Pharmacother 2020; 121: 109637
• 105 Ho DW, Tsui YM, Chan LK. et al. Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. Nat Commun 2021; 12 (01) 3684
• 106 Tang F, Li J, Qi L. et al. A pan-cancer single-cell panorama of human natural killer cells. Cell 2023; 186 (19) 4235-4251.e20
• 107 Morita S, Kikuchi H, Birch G. et al. Preventing NK cell activation in the damaged liver induced by cabozantinib/PD-1 blockade increases survival in hepatocellular carcinoma models. bioRxiv 2023
• 108 Patente TA, Pinho MP, Oliveira AA, Evangelista GCM, Bergami-Santos PC, Barbuto JAM. Human dendritic cells: their heterogeneity and clinical application potential in cancer immunotherapy. Front Immunol 2019; 9: 3176
• 109 Del Prete A, Salvi V, Soriani A. et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol 2023; 20 (05) 432-447
• 110 Guilliams M, Dutertre CA, Scott CL. et al. Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species. Immunity 2016; 45 (03) 669-684
• 111 Villar J, Segura E. Decoding the heterogeneity of human dendritic cell subsets. Trends Immunol 2020; 41 (12) 1062-1071
• 112 Zhu C, Ma J, Zhu K. et al. Spatial immunophenotypes predict clinical outcome in intrahepatic cholangiocarcinoma. JHEP Rep Innov Hepatol 2023; 5 (08) 100762
• 113 Bronte V, Brandau S, Chen SH. et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 2016; 7: 12150
• 114 Lasser SA, Ozbay Kurt FG, Arkhypov I, Utikal J, Umansky V. Myeloid-derived suppressor cells in cancer and cancer therapy. Nat Rev Clin Oncol 2024; 21 (02) 147-164
• 115 Yang S, Jia J, Wang F. et al. Targeting neutrophils: mechanism and advances in cancer therapy. Clin Transl Med 2024; 14 (03) e1599
• 116 Ma T, Renz BW, Ilmer M. et al. Myeloid-derived suppressor cells in solid tumors. Cells 2022; 11 (02) 11
• 117 Arihara F, Mizukoshi E, Kitahara M. et al. Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother 2013; 62 (08) 1421-1430
• 118 Massalha H, Bahar Halpern K, Abu-Gazala S. et al. A single cell atlas of the human liver tumor microenvironment. Mol Syst Biol 2020; 16 (12) e9682
• 119 Fujita M, Yamaguchi R, Hasegawa T. et al. Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations. EBioMedicine 2020; 53: 102659
• 120 Martin-Serrano MA, Kepecs B, Torres-Martin M. et al. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut 2023; 72 (04) 736-748
• 121 Lin J, Dai Y, Sang C. et al. Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities. J Immunother Cancer 2022; 10 (07) 10
• 122 Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell 2018; 33 (04) 581-598
• 123 Job S, Rapoud D, Dos Santos A. et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. Hepatology 2020; 72 (03) 965-981
• 124 Kurebayashi Y, Ojima H, Tsujikawa H. et al. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology 2018; 68 (03) 1025-1041
• 125 Bagaev A, Kotlov N, Nomie K. et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 2021; 39 (06) 845-865.e7
• 126 Zhang Q, Lou Y, Yang J. et al. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut 2019; 68 (11) 2019-2031
• 127 Montironi C, Castet F, Haber PK. et al. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut 2023; 72 (01) 129-140
• 128 Zhang H, Yao Y, Wu J. et al. Comprehensive analysis identifies and validates the tumor microenvironment subtypes to predict anti-tumor therapy efficacy in hepatocellular carcinoma. Front Immunol 2022; 13: 838374
• 129 Maestri E, Kedei N, Khatib S. et al. Spatial proximity of tumor-immune interactions predicts patient outcome in hepatocellular carcinoma. Hepatology 2024; 79 (04) 768-779
• 130 Revsine M, Wang L, Forgues M. et al. Lineage and ecology define liver tumor evolution in response to treatment. Cell Rep Med 2024; 5 (02) 101394
• 131 Moffitt JR, Lundberg E, Heyn H. The emerging landscape of spatial profiling technologies. Nat Rev Genet 2022; 23 (12) 741-759
• 132 Biancalani T, Scalia G, Buffoni L. et al. Deep learning and alignment of spatially resolved single-cell transcriptomes with Tangram. Nat Methods 2021; 18 (11) 1352-1362
• 133 Abdelaal T, Mourragui S, Mahfouz A, Reinders MJT. SpaGE: spatial gene enhancement using scRNA-seq. Nucleic Acids Res 2020; 48 (18) e107-e107
• 134 Wan X, Xiao J, Tam SST. et al. Integrating spatial and single-cell transcriptomics data using deep generative models with SpatialScope. Nat Commun 2023; 14 (01) 7848
• 135 Kirschenbaum D, Xie K, Ingelfinger F. et al. Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma. Cell 2024; 187 (01) 149-165.e23
• 136 Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol 2016; 64 (01) S84-S101
• 137 Goto K, Roca Suarez AA, Wrensch F, Baumert TF, Lupberger J. Hepatitis C virus and hepatocellular carcinoma: when the host loses its grip. Int J Mol Sci 2020; 21 (09) 21
• 138 Mackowiak B, Fu Y, Maccioni L, Gao B. Alcohol-associated liver disease. J Clin Invest 2024; 134 (03) 134
• 139 Parthasarathy G, Revelo X, Malhi H. Pathogenesis of nonalcoholic steatohepatitis: an overview. Hepatol Commun 2020; 4 (04) 478-492
• 140 Zheng Q, Sun Q, Yao H. et al. Single-cell landscape identifies the immunophenotypes and microenvironments of HBV-positive and HBV-negative liver cancer. Hepatol Commun 2024; 8 (02) 8
• 141 Li M, Wang L, Cong L. et al. Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Hepatology 2023;•••
• 142 Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004; 172 (05) 2731-2738
• 143 Brown ZJ, Heinrich B, Greten TF. Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research. Nat Rev Gastroenterol Hepatol 2018; 15 (09) 536-554
• 144 Jeon SH, Lee YJ, Kim HD. et al. Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma. Cancer Immunol Immunother 2023; 72 (02) 371-384
• 145 Kim HD, Jung S, Lim HY. et al. Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nat Med 2024; 30 (03) 699-707
• 146 Simoni Y, Becht E, Fehlings M. et al. Bystander CD8⁺ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 2018; 557 (7706) 575-579
• 147 Liu L, Liu J, Li P. et al. Single-cell analysis reveals HBV-specific PD-1⁺CD8⁺ TRM cells in tumor borders are associated with HBV-related hepatic damage and fibrosis in HCC patients. J Exp Clin Cancer Res 2023; 42 (01) 152
• 148 Xie Z, Huang J, Li Y. et al. Single-cell RNA sequencing revealed potential targets for immunotherapy studies in hepatocellular carcinoma. Sci Rep 2023; 13 (01) 18799